[A18-56] Tofacitinib (rheumatoid arthritis) - Addendum to Commission A18-28



Commission: Commission awarded on 2018-09-11 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A18-28  [PDF, 123 kB] (German version) Further documents

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A18-28] Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed

Report documents

Report documents

2018-11-07 Addendum to Commission A18-28 (German version) 123 kBPDFdownload file

At a glance

Accompanying information

Federal Joint Committee (G-BA)

2018-11-07 A G-BA decision was published.

G-BA documents on this decision

Save result list

To save your search result, please copy the link below and paste it into a new tab/window.